Ezra E.W. Cohen

2003–2026 年に発表

別表記
Ezra E. W. Cohen
145
論文数
24,870
被引用数
84
h 指数
141
i10 指数

被引用数

Ezra E.W. Cohen の年別被引用数1956 年: 被引用 1 件1976 年: 被引用 1 件1992 年: 被引用 1 件1995 年: 被引用 5 件2001 年: 被引用 1 件2003 年: 被引用 7 件2004 年: 被引用 27 件2005 年: 被引用 42 件2006 年: 被引用 53 件2007 年: 被引用 67 件2008 年: 被引用 72 件2009 年: 被引用 83 件2010 年: 被引用 114 件2011 年: 被引用 145 件2012 年: 被引用 170 件2013 年: 被引用 167 件2014 年: 被引用 148 件2015 年: 被引用 143 件2016 年: 被引用 184 件2017 年: 被引用 220 件2018 年: 被引用 226 件2019 年: 被引用 903 件2020 年: 被引用 1,090 件2021 年: 被引用 1,207 件2022 年: 被引用 988 件2023 年: 被引用 733 件2024 年: 被引用 1,150 件2025 年: 被引用 576 件2026 年: 被引用 15 件1957〜1975 年は被引用が無いため表示していません1977〜1991 年は被引用が無いため表示していません1993〜1994 年は被引用が無いため表示していません1996〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,013 件、この内訳の 27.9%中国: 引用元論文 1,532 件、この内訳の 14.2%イタリア: 引用元論文 596 件、この内訳の 5.5%イギリス: 引用元論文 509 件、この内訳の 4.7%ドイツ: 引用元論文 460 件、この内訳の 4.3%フランス: 引用元論文 407 件、この内訳の 3.8%カナダ: 引用元論文 352 件、この内訳の 3.3%日本: 引用元論文 320 件、この内訳の 3%スペイン: 引用元論文 300 件、この内訳の 2.8%オーストラリア: 引用元論文 264 件、この内訳の 2.4%オランダ: 引用元論文 262 件、この内訳の 2.4%インド: 引用元論文 226 件、この内訳の 2.1%
0%27.9%その他 23.6%

分野

  • Medicine63%
  • Biochemistry, Genetics and Molecular Biology19.2%
  • Immunology and Microbiology10.7%
  • Engineering1.6%
  • Dentistry1.6%
  • Health Professions0.8%
  • その他3.1%

トピック

  • Cancer Immunotherapy and Biomarkers7.9%
  • Head and Neck Cancer Studies7.5%
  • Immunotherapy and Immune Responses3.3%
  • Immune cells in cancer3.1%
  • Lung Cancer Treatments and Mutations3%
  • Thyroid Cancer Diagnosis and Treatment2.4%
  • その他72.8%

共著者

全論文

検索で開く
  1. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland ほか 13 名 - The Lancet 2018 被引用: 1,697

  2. PI3Kγ is a molecular switch that controls immune suppression

    著者: , , , , , , , , , , , , , , , , , , , , , , - Nature 2016 被引用: 1,174

  3. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 617

  4. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

    著者: , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 被引用: 738

  5. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 258

  6. Cabozantinib in Progressive Medullary Thyroid Cancer

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 1,215

  7. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 被引用: 174

  8. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zoltán Takácsi Nagy, Ju‐Whei Lee, Catherine Fortpied, Jonathan Harris, Jean Bourhis, Anne Aupérin, Pierre Blanchard, Jean‐Pierre Pignon, David J. Adelstein, M. Alfonsi, Y. Belkacemi, Voichita Bar‐Ad, J. Bernier, Åse Bratland, G. Calais, Brittany Campbell, Jimmy J. Caudell, Sylvie Chabaud, Emmanuel Chamorey, Devendra Chaukar, Kwang Nam Choi, Olivier Choussy, Laurence Collette, Judith Cruz, Carla Dani, Etienne Dauzier, Arlene A. Forastiere, P. Garaud, V. Grégoire, A. Hackshaw, E. Haddad, Bruce G. Haffty, Aaron R. Hansen, Stefanie Hayoz, Jean-Claude Horiot, Branislav Jeremić, Theodore Karrison, Johannes A. Langendijk, M. Lapeyre, Éric Lartigau, Traci Leong, Quynh‐Thu Le, Patricia Lee, Freddi Lewin, Aihua Lin, Alberto Lopes, Samir Mehta, James Moon, Elizabeth Moyal, Bob‐Valéry Occéan, P. Olmi, Roberto Orecchia, Brian O’Sullivan, Jens Overgaard, Claire Petit, Harvey Quon, Giuseppe Sanguineti, Tuvana Satar, John Simes, Christian Simon, Clément Sire, S. Staar, C. Stromberger, P. Strojan, Stéphane Temam, David Thomson, A. Timochenko, Valter Torri, Vassilikì Tseroni, Jan B. Vermorken ほか 5 名 - Radiotherapy and Oncology 2021 被引用: 376

  9. The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification

    著者: , , , , - Clinical Cancer Research 2020 被引用: 200

  10. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

    著者: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 被引用: 78

  11. Positive Surgical Margins in the 10 Most Common Solid Cancers

    著者: , , , , , , , , , , , , , , - Scientific Reports 2018 被引用: 278

  12. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade

    著者: , , , , , , , , , - Clinical Cancer Research 2020 被引用: 203

  13. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2014 被引用: 658

  14. American Cancer Society Head and Neck Cancer Survivorship Care Guideline

    著者: , , , , , , , , , , , - CA A Cancer Journal for Clinicians 2016 被引用: 607

  15. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

    著者: , , , , , , , , , , , , , , , , - JCI Insight 2017 被引用: 287

  16. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

    著者: , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 108

  17. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

    著者: , , , , , , , - The Lancet Oncology 2016 被引用: 384

  18. Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors

    著者: , , , , , , , , , , , , - Nature Immunology 2023 被引用: 79

  19. Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients

    著者: , , , , , - Clinical Cancer Research 2021 被引用: 83

  20. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4

    著者: , , , , , , , , , , , , , , , , , , - Nature Communications 2019 被引用: 173

  21. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

    著者: , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 被引用: 111

  22. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

    著者: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 48

  23. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine

    著者: , , , , , , , , , , , , - Clinical Cancer Research 2017 被引用: 131

  24. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 239